FDA Committee Recommends Clearance for Immucor Blood-Typing Chip | GenomeWeb

NEW YORK (GenomeWeb News) – Immucor announced after the close of the market Tuesday that a US Food and Drug Administration committee has recommended that its platform for human erythrocyte antigen typing be cleared for clinical use.

The FDA's Blood Products Advisory Committee decided that Immucor's HEA Molecular BeadChip is "safe and effective" for typing HEA phenotypes in 35 blood group systems, the Norcross, Ga.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.